A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor

Summary

Tafetinib is an oral multitargeted tyrosine kinase inhibitor that inhibits Vascular Endothelial Growth Factor Receptor (VEGFR). This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of tafetinib in Chinese patients with advance solid tumor. The study are conducting in Cancer Hospital Chinese Academy of Medical Sciences.

Timeline

Start

2015-05

Primary completion

2017-04

Completion

2017-04

Drugs

Indications